

Additions and Corrections

2007, Volume 50

Mikko J. Myllymäki, Susanna M. Saario, Antti O. Kataja, Joel A. Castillo-Melendez, Tapio Nevalainen, Risto O. Juvonen, Tomi Järvinen, and Ari M. P. Koskinen*: Design, Synthesis, and In Vitro Evaluation of Carbamate Derivatives of 2-Benzoxazolyl- and 2-Benzothiazolyl-(3-hydroxyphenyl)-methanones as Novel Fatty Acid Amide Hydrolase Inhibitors.

Page 4238. In Table 1 in the row for compound **23**, the reference number in the 11th column labeled "IC₅₀ (95% CI)^a FAH" should be "30" instead of "25" and the reference number in the 12th column labeled "MAGL" should be "15" instead of "11". In the row for compound **24** and in the 11th column labeled "IC₅₀ (95% CI)^a FAH", the reference number should be "29" instead of "24" and the K_i value should be "2.3 nM" instead of "0.23 nM".

JM701230U

10.1021/jm701230u

Published on Web 10/18/2007

2005, Volume 48

Michael J. Costanzo,* Harold R. Almond, Jr., Leonard R. Hecker, Mary R. Schott, Stephen C. Yabut, Han-Cheng Zhang, Patricia Andrade-Gordon, Thomas W. Corcoran, Edward C. Giardino, Jack A. Kauffman, Joan M. Lewis, Lawrence de Garavilla, Barbara J. Haertlein, and Bruce E. Maryanoff*: In-Depth Study of Tripeptide-Based α -Ketoheterocycles as Inhibitors of Thrombin. Effective Utilization of the S₁' Subsite and Its Implications to Structure-Based Drug Design.

Page 1992. Structures **41** and **42** in Scheme 4 should have a CH₂ group inserted between the cyclohexane ring and the NH₂ group.

Page 2005. In ref 3a, the term "Asp-104" is incorrect and should be replaced by "Asp-102".

JM701211Q

10.1021/jm701211q

Published on Web 10/12/2007